Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03672006 · ClinicalTrials.gov registry record · Phase 2
t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection
A Phase 2 study of Central Venous Catheter Thrombosis and Central Venous Catheter Associated Bloodstream Infection, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03672006: Completed Phase 2 study of Central Venous Catheter Thrombosis and Central Venous Catheter Associated Bloodstream Infection, sponsored by Medical College of Wisconsin.
NCT03672006 is a Phase 2 study of Central Venous Catheter Thrombosis and Central Venous Catheter Associated Bloodstream Infection that has completed, run by Medical College of Wisconsin. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03672006, a Phase 2 study of Central Venous Catheter Thrombosis and Central Venous Catheter Associated Bloodstream Infection, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to test feasibility of concept, consent and enrollment rates, and mechanics of study designed to assess if intra-catheter dwells of tissue plasminogen activator (t-PA) is effective in decreasing the rate of clinically diagnosed central line associated blood stream infection (CLABSI) or venous thromboembolism (VTE) in central venous catheters (CVC) compared to standard of care heparin dwell.
Primary Outcome
Catheter-associated Venous Thrombosis upon ICU discharge or 30 days
Conditions Studied
Interventions
- DRUG Heparin
- BIOLOGICAL alteplase (recombinant t-PA)
Study Locations (1)
Wisconsin
- Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-04-22 |
| Est. Completion | 2019-12-15 |
| Phase | Phase 2 |
What the finished NCT03672006 record still lists
NCT03672006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Central Venous Catheter Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Heparin is the first listed.
NCT03672006 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03672006 about?
NCT03672006 is a clinical study titled "t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection". The purpose of this pilot study is to test feasibility of concept, consent and enrollment rates, and mechanics of study designed to assess if intra-catheter dwells of tissue plasminogen activator (t-PA) is effective in decreasing the rate of clinically diagnosed central line associated blood stream ...
What is the current status of trial NCT03672006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-04-22. Estimated completion is 2019-12-15.
What conditions does trial NCT03672006 study?
This clinical trial studies the following conditions: Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection.
What interventions are being tested in trial NCT03672006?
The interventions under investigation include: Heparin (DRUG), alteplase (recombinant t-PA) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03672006?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03672006 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03672006's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI